希腊轻度认知障碍和痴呆症的地理分布和未来预测:从1991年到2050年的分析
Themis P Exarchos1,2, Konstantina Skolariki3, Vasiliki Mahairaki4
1Bioinformatics and Human Electrophysiology Laboratory, Department of Informatics, Ionian University, 49132 Corfu, Greece.
Brain sciences
|June 26, 2025
概括
希腊面临着轻度认知障碍 (MCI) 和痴呆症的日益严重的流行病,预计病例将大幅增加. 这凸显了区域医疗保健规划的迫切需要,以支持人口老龄化.
科学领域:
- 老年学与公共卫生
- 认知衰退的流行病学
- 在老龄化社会中医疗保健规划
背景情况:
- 希腊是世界上人口老龄化最快的国家之一.
- 希腊轻度认知障碍 (MCI) 和痴呆症的高患病率,超过欧洲平均水平.
- 在希腊的认知障碍病例分布中存在显著的区域差异.
研究的目的:
- 估计希腊患有MCI和痴呆症的人数.
- 使用热图可视化MCI和痴呆病例的区域分布.
- 为医疗保健规划预测MCI和痴呆症患病率的未来趋势.
主要方法:
- 利用1991年,2001年,2011年和2023年的人口普查数据进行估计.
- 应用年龄和性别特定的患病率来自希腊老龄化和饮食的纵向调查.
- 创建区域热图以说明疾病负担和分布.
主要成果:
- 患有MCI的病例从177,898 (1991) 增加到311,189 (2023);痴呆病例从103,535 (1991) 增加到206,939 (2023).
- 未来的预测显示,到2050年,MCI病例将超过44万例,痴呆症病例将超过31万例.
- 热图揭示了认知障碍患病率的地区差异相当大.
结论:
- 希腊不断升级的痴呆症流行病对希腊构成了重大挑战,影响了护理需求.
- 区域热图是政策制定者设计有针对性的临床护理计划的关键工具.
- 积极的计划对于解决希腊日益增长的认知衰退负担至关重要.
相关概念视频
01:30Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:30Cognitive Development During Adulthood
303
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
303
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214